Evidence map›Paper›PMID 11691935›Full record

ArticleNucleic acids research2001

A gene required for the novel activation of a class II DNA photolyase in Chlamydomonas.

J L Petersen, G D Small

Open access · bronzeAbstract read
In one paragraph

Article in Nucleic acids research, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

J L PetersenCellular and Molecular Biology Research Group, University of South Dakota, 414 East Clark Street, Vermillion, SD 57069-2390, USA.
G D Small
University of South Dakota · US

Funding

BLUE-LIGHT PHOTORECEPTOR GENES IN CHLAMYDOMONASR15GM059857 · NIGMS · UNIVERSITY OF SOUTH DAKOTA · PI SMALL, GARY D · 1999 to 1999
–
NIGMS NIH HHS GM59857
6 · The paper itself

Abstract

DNA photolyases catalyze the blue light-dependent repair of UV light-induced damage in DNA. DNA photolyases are specific for either cyclobutane-type pyrimidine dimers or (6-4) photoproducts. PHR2 is a gene that in Chlamydomonas reinhardtii encodes a class II DNA photolyase which catalyzes the photorepair of cyclobutane-type pyrimidine dimers. Based on amino acid sequence analysis of PHR2, which indicates the presence of a chloroplast targeting sequence, PHR2 was predicted to encode the chloroplast photolyase of Chlamydomonas. Using a sensitive gene-specific in vivo repair assay, we found that overexpression of PHR2 in Chlamydomonas results in targeting of the protein to not only the chloroplast, but also to the nucleus. Overexpression of PHR2 photolyase in a photoreactivation-deficient mutant, phr1, results in a largely inactive product. The phr1 mutant was found to be deficient in both photorepair of a chloroplast gene, rbcL, and a nuclear gene, rDNA. These results suggest that PHR2 is the structural gene for the photolyase targeted to both the chloroplast and the nucleus, and that the PHR1 gene product is necessary for full activity of PHR2 protein. To our knowledge, the requirement for a second gene for full activity of a DNA photolyase is novel.

Indexed as

Fungal ProteinsMembrane GlycoproteinsAnimalsApoenzymesBlotting, WesternCell NucleusChlamydomonas reinhardtiiChloroplastsDeoxyribodipyrimidine Photo-LyaseDNADNA, ChloroplastDNA DamageDNA RepairDNA, RibosomalElectrophoretic Mobility Shift AssayEnzyme ActivationApoenzymesDeoxyribodipyrimidine Photo-LyaseDNADNA, ChloroplastDNA, RibosomalFungal ProteinsMembrane GlycoproteinsPHR1 protein, Candida albicansPyrimidine Dimers

Identifiers

PMID11691935
PMCPMC60191
OpenAlexW2120542127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.